BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal

 
• By Alaric DeArment

Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.

Cancer - DNA - test tube
BMS signed a deal with Volastra focused on synthetic lethality in oncology • Source: Shutterstock

More from Anticancer

More from Therapy Areas